Taro Pharmaceutical Industries Ltd
NYSE:TARO
Taro Pharmaceutical Industries Ltd
NYSE:TARO
Price:
42.3 USD
-0.26%
Market Closed
Updated:
May 13, 2024
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT
31.3
Current
8.1
Median
17.5
Industry
Higher
than median
Higher
than industry value
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
EV/EBIT
=31.3
Enterprise Value
/
687.7m
EBIT
22m
All Countries
| Market Cap | EV/EBIT | ||||
|---|---|---|---|---|---|
| IL |
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
1.6B USD | 31.3 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.3B USD | 65.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 36.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.8B USD | 15.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
329.4B USD | 58.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
191.8B GBP | 278.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
180.6B CHF | 12.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
179.5B CHF | 10.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.1B USD | 20.2 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBIT
-543.3
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A
You don't have any saved screeners yet
